- Report
- May 2022
- 510 Pages
Global
From €2423EUR$2,550USD£2,077GBP
€2850EUR$3,000USD£2,444GBP
- Drug Pipelines
- March 2022
- 900 Pages
Global
From €7268EUR$7,650USD£6,232GBP
€8550EUR$9,000USD£7,332GBP
- Report
- February 2022
- 360 Pages
United States
From €2907EUR$3,060USD£2,493GBP
€3420EUR$3,600USD£2,933GBP
- Report
- December 2021
- 120 Pages
Global
From €2665EUR$2,805USD£2,285GBP
€3135EUR$3,300USD£2,688GBP
- Report
- April 2021
- 180 Pages
Global
From €2423EUR$2,550USD£2,077GBP
€2850EUR$3,000USD£2,444GBP
- Report
- February 2021
- 330 Pages
Global
From €1938EUR$2,040USD£1,662GBP
€2280EUR$2,400USD£1,955GBP
- Report
- February 2020
- 600 Pages
Global
From €3230EUR$3,400USD£2,770GBP
€3800EUR$4,000USD£3,259GBP
- Report
- September 2021
- 143 Pages
Global
From €2613EUR$2,750USD£2,240GBP
€5225EUR$5,500USD£4,481GBP
- Report
- March 2021
- 143 Pages
Global
From €1306EUR$1,375USD£1,120GBP
€2613EUR$2,750USD£2,240GBP
- Report
- July 2019
- 21 Pages
Global
From €594EUR$625USD£509GBP
€1188EUR$1,250USD£1,018GBP
- Report
- December 2018
- 288 Pages
Global
From €1306EUR$1,375USD£1,120GBP
€2613EUR$2,750USD£2,240GBP
- Report
- October 2018
- 141 Pages
Global
From €594EUR$625USD£509GBP
€1188EUR$1,250USD£1,018GBP
- Report
- August 2018
- 86 Pages
Global
From €5653EUR$5,950USD£4,847GBP
- Report
- October 2019
- 189 Pages
Global
From €3943EUR$4,150USD£3,381GBP
- Report
- October 2018
- 370 Pages
Global
From €3943EUR$4,150USD£3,381GBP
- Report
- May 2024
- 128 Pages
From €6174EUR$6,499USD£5,294GBP
- Report
- May 2024
- 129 Pages
From €6174EUR$6,499USD£5,294GBP
- Report
- May 2024
- 137 Pages
From €6174EUR$6,499USD£5,294GBP
- Report
- May 2024
- 138 Pages
From €6174EUR$6,499USD£5,294GBP
- Report
- May 2024
- 137 Pages
From €6174EUR$6,499USD£5,294GBP
Immune Checkpoint Inhibitor drugs are a type of immunotherapy used to treat immune disorders. They work by blocking proteins that act as “checkpoints” in the immune system, allowing the body to recognize and attack cancer cells. These drugs are used to treat a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer. They are also used to treat autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease.
Immune Checkpoint Inhibitor drugs are a relatively new form of treatment, and the market is still in its early stages. However, the potential of these drugs has led to a surge in research and development, with many companies investing in the development of new drugs.
Some of the major companies in the Immune Checkpoint Inhibitor market include Bristol-Myers Squibb, Merck, AstraZeneca, Roche, and Novartis. Other companies such as Pfizer, AbbVie, and Johnson & Johnson are also involved in the development of these drugs. Show Less Read more